Login / Signup

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.

Arsenne MekinianLin-Pierre ZhaoSylvie ChevretKristell DesseauxLaurent PascalThibaut ComontAlexandre MariaPierre PeterlinLouis TerriouMaud D'Aveni PineyMarie-Pierre GourinNorbert VeyOdile Beyne RauzyVincent GrobostHoly BezanaharySophie Dimicoli-SalazarAnne BanosStefan WickenhauserBenoit De RenzisEric DurotShanti Natarajan-AméLaurent VoillatFatiha ChermatKarine LemaireVincent JachietChantal HimberlinSylvain ThépotJose Miguel Torregrosa DiazLaurent FrenzelEmmanuel GyanGuillaume DenisPierre HirschOlivier KosmiderLionel AdesOlivier FainPierre Fenaux
Published in: Leukemia (2022)
Keyphrases
  • phase ii
  • clinical trial
  • open label
  • phase iii
  • acute myeloid leukemia
  • multiple sclerosis
  • double blind
  • placebo controlled
  • oxidative stress
  • drug induced
  • case report
  • study protocol
  • randomized controlled trial